Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Guluronic Acid (G2013) on Ship1, Socs1 Induction and Related Molecules in Tlr4 Signaling Pathway Publisher Pubmed



Mortazavijahromi SS1, 3 ; Farazmand A1, 2 ; Motamed N1, 2 ; Navabi SS3 ; Mirshafiey A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Kish, Iran
  2. 2. School of Biology, University College of Science, University of Tehran, Tehran, Iran
  3. 3. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: International Immunopharmacology Published:2018


Abstract

Objective This research aimed to study the anti-inflammatory and immunomodulatory effects of guluronic acid (G2013) on gene expression of TLR4, MyD88, SHIP1, SOCS1, NF-κB, and assessment of the level of IL-1β as a pro-inflammatory cytokine in HEK-Blue hTLR4 cell line. Methods The cytotoxicity of G2013 was assessed by the MTT assay. The mRNA expression levels of the mentioned genes were measured by qRT-PCR. IL-1β concentration in culture media was determined using ELISA method. Results MTT assay demonstrated that G2013 (before the concentration of 125 μg/ml) had no cytotoxic effect on HEK-Blue hTLR4 cells. Our results indicated that the low and high doses of this drug could significantly reduce the gene expression of TLR4 and MyD88, as compared to the control group (p < 0.05). Moreover, it was found that the low dose of this drug could significantly increase the gene expression of SHIP1 and SOCS1, as compared to the control group (p < 0.05). Furthermore, the study findings revealed that the level of NF-κB gene expression significantly reduced, in both doses of G2013 compared to the control group (p < 0.05, p < 0.01, respectively). Our data showed that the level of IL-1β in culture media decreased by both doses of this drug in comparison to control group (p < 0.05). Conclusion This study indicates that G2013 is able to induce SHIP1, SOCS1 and reduce TLR4, MyD88, NF-κB at the level of gene expression and decrease IL-1β as a pro-inflammatory cytokine which might be recommended for reduction of inflammatory reactions. © 2018 Elsevier B.V.
Related Docs
View other Related Docs
1. Evaluation of the Effect of Α-L-Guluronic Acid (G2013) on Cox-1, Cox-2 Activity and Gene Expression for Introducing This Drug As a Novel Nsaid With Immunomodulatory Property, Recent Patents on Inflammation and Allergy Drug Discovery (2018)
2. Immunomodulatory Effect of G2013 (Α-L-Guluronic Acid) on the Tlr2 and Tlr4 in Human Mononuclear Cells, Current Drug Discovery Technologies (2018)
3. Immunopharmacological Effect of Β-D-Mannuronic Acid (M2000), As a New Immunosuppressive Drug, on Gene Expression of Mir-155 and Its Target Molecules (Socs1, Ship1) in a Clinical Trial on Rheumatoid Arthritis Patients, Drug Development Research (2020)
4. The Immunomodulatory Role of G2013 (Α-L-Guluronic Acid) on the Expression of Tlr2 and Tlr4 in Ht29 Cell Line, Current Drug Discovery Technologies (2019)
5. The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on Sars-Cov-2 Patients, Current Drug Discovery Technologies (2023)
6. Inhibitory Effect of G2013 Molecule As a Novel Immunomodulatory Agent, on Mir-155 Gene Expression in Hek-Blue Htlr4 Cell Line, European Journal of Inflammation (2016)
7. Assessment of Immunological Profile in Ankylosing Spondylitis Patients Following a Clinical Trial With Guluronic Acid (G2013), As a New Nsaid With Immunomodulatory Properties, Immunologic Research (2019)
8. The Application of G2013 (Α-L-Guluronic Acid) As an Anti-Inflammatory Drug Candidate in Treatment of Disease, Journal of Isfahan Medical School (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (8)
Laleh Sharifi (4)
Other Related Docs
9. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) As a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes, Endocrine# Metabolic and Immune Disorders - Drug Targets (2020)
10. An in Vitro Evaluation of Anti-Aging Effect of Guluronic Acid (G2013) Based on Enzymatic Oxidative Stress Gene Expression Using Healthy Individuals Pbmcs, Biomedicine and Pharmacotherapy (2017)
11. Anti‐Inflammatory and Anti‐Tumor Effects of Α-L-Guluronic Acid (G2013) on Cancer-Related Inflammation in a Murine Breast Cancer Model, Biomedicine and Pharmacotherapy (2018)
12. Pharmacological Effects of Β-D-Mannuronic Acid (M2000) on Mir-146A, Irak1, Traf6 and Nf-Κb Gene Expression, As Target Molecules in Inflammatory Reactions, Pharmacological Reports (2017)
13. A Randomized Clinical Trial for the Assessment of the Efficacy and Safety of Guluronic Acid (G2013) in Patients With Rheumatoid Arthritis, Immunopharmacology and Immunotoxicology (2019)
14. Pivotal Cytokines and Their Transcription Factors Are the Targets of Guluronic Acid (G2013) for Inhibiting the Immunopathogenesis Process of Multiple Sclerosis, Drug Development Research (2020)
15. Evaluation of the Oral Administration of Α-L-Guluronic Acid on Cox-1 and Cox-2 Gene Expression Profile in Ankylosing Spondylitis Patients, Drug Development Research (2021)
16. The Role of M2000 As an Anti-Inflammatory Agent in Toll-Like Receptor 2/Microrna-155 Pathway, Avicenna Journal of Medical Biotechnology (2017)
17. The Potent Suppressive Effect of Β-D-Mannuronic Acid (M2000) on Molecular Expression of the Tlr/Nf-Kb Signaling Pathway in Ankylosing Spondylitis Patients, International Immunopharmacology (2017)
18. Effects of Guluronic Acid (G2013) on Gene Expression of Tlr2, Tlr4, Myd88, Tnf-Α and Cd52 in Multiple Sclerosis Under in Vitro Conditions, Immunopharmacology and Immunotoxicology (2019)
19. Evaluation of the Acute and 28-Day Sub-Acute Intravenous Toxicity of Α-L-Guluronic Acid (Alg; G2013) in Mice, Drug and Chemical Toxicology (2022)
20. Preclinical and Pharmacotoxicology Evaluation of Α-L-Guluronic Acid (G2013) As a Non-Steroidal Anti-Inflammatory Drug With Immunomodulatory Property, Immunopharmacology and Immunotoxicology (2017)
21. The Effects of Guluronic Acid (G2013), a New Emerging Treatment, on Inflammatory Factors in Nonalcoholic Steatohepatitis Patients Under in Vitro Conditions, Immunopharmacology and Immunotoxicology (2021)
22. The Evaluation of Safety Property and Apoptotic Efficacy of Α-L-Guluronic Acid (G2013), As a Novel Nsaid, Under in Vitro Examination on L929 and Hepatocellular Carcinoma Cell Lines, Recent Advances in Inflammation and Allergy Drug Discovery (2021)
23. Antagonistic Property of G2013 (Α-L-Guluronic Acid) on Gene Expression of Myd88, Tollip, and Nf-Κb in Hek293 Tlr2 and Hek293 Tlr4, Endocrine# Metabolic and Immune Disorders - Drug Targets (2019)
24. Effects of Guluronic Acid, As a New Nsaid With Immunomodulatory Properties on Il-17, Rorγt, Il-4 and Gata-3 Gene Expression in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)
25. Evaluation of G2013 (Α-L-Guluronic Acid) Efficacy on Pc-3 Cells Through Inhibiting the Expression of Inflammatory Factors, Clinical and Experimental Pharmacology and Physiology (2022)
26. The Safety and Efficacy of Guluronic Acid (G2013) in Ankylosing Spondylitis: A Randomized Controlled Parallel Clinical Trial, Pharmacological Reports (2019)
27. Role of Toll-Like Receptors in Inflammatory Bowel Disease, Pharmacological Research (2018)
28. Effect of Guluronic Acid (G2013), As a New Anti-Inflammatory Drug on Gene Expression of Pro-Inflammatory and Anti-Inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients, Iranian Journal of Allergy# Asthma and Immunology (2019)
29. Modulation of the Immune System Promotes Tissue Regeneration, Molecular Biotechnology (2022)
30. Vaccines, Adjuvants, and Delivery Systems, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
31. Monocytic Tlr4 Expression and Activation in Schizophrenia: A Systematic Review and Meta-Analysis, PLoS ONE (2025)
32. The Effects of G2013 (Α-L-Guluronic Acid) in a Pentylenetetrazole-Induced Kindling Animal Model of Epilepsy, Innovations in Clinical Neuroscience (2020)
33. Therapeutic Targeting of Toll-Like Receptors: A Review of Toll-Like Receptors and Their Signaling Pathways in Psoriasis, Expert Review of Clinical Immunology (2016)
34. Dysregulated Mirnas Network in the Critical Covid-19: An Important Clue for Uncontrolled Immunothrombosis/Thromboinflammation, International Immunopharmacology (2022)
35. Efficacy and Safety of G2013 As a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells, Iranian Journal of Public Health (2017)
36. The Role of Toll-Like Receptors in Neuropsychiatric Disorders: Immunopathology, Treatment, and Management, Medicinal Research Reviews (2024)
37. Vaccines, Adjuvants, and Delivery Systems, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
38. Immunomodulation of Tlr2 and Tlr4 by G2013 (Α-L-Guluronic Acid) in Cvid Patients, International Journal of Pediatrics (2017)
39. Upregulation of Toll-Like Receptor 4 Through Anti-Mir-Let-7A Enhances Blastocyst Attachment to Endometrial Cells in Mice, Journal of Cellular Physiology (2020)